ATE248592T1 - Verwendung von naaladase hemmern zur herstellung eines medikaments zur behandlung von bestimmten krankheiten - Google Patents
Verwendung von naaladase hemmern zur herstellung eines medikaments zur behandlung von bestimmten krankheitenInfo
- Publication number
- ATE248592T1 ATE248592T1 AT99967675T AT99967675T ATE248592T1 AT E248592 T1 ATE248592 T1 AT E248592T1 AT 99967675 T AT99967675 T AT 99967675T AT 99967675 T AT99967675 T AT 99967675T AT E248592 T1 ATE248592 T1 AT E248592T1
- Authority
- AT
- Austria
- Prior art keywords
- medication
- produce
- treatment
- certain diseases
- naaladase inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract 1
- 102000003958 Glutamate Carboxypeptidase II Human genes 0.000 abstract 1
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000024245 cell differentiation Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 210000002744 extracellular matrix Anatomy 0.000 abstract 1
- 230000036737 immune function Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000003908 liver function Effects 0.000 abstract 1
- 230000023105 myelination Effects 0.000 abstract 1
- 230000035771 neuroregeneration Effects 0.000 abstract 1
- 230000004203 pancreatic function Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22429198A | 1998-12-31 | 1998-12-31 | |
| US09/425,197 US6444657B1 (en) | 1998-12-31 | 1999-10-22 | Methods for treating certain diseases using naaladase inhibitors |
| PCT/US1999/031039 WO2000038785A2 (en) | 1998-12-31 | 1999-12-29 | Methods for treating certain diseases using naaladase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE248592T1 true ATE248592T1 (de) | 2003-09-15 |
Family
ID=26918579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99967675T ATE248592T1 (de) | 1998-12-31 | 1999-12-29 | Verwendung von naaladase hemmern zur herstellung eines medikaments zur behandlung von bestimmten krankheiten |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6444657B1 (de) |
| EP (2) | EP1140048B1 (de) |
| JP (1) | JP2002533421A (de) |
| AT (1) | ATE248592T1 (de) |
| AU (1) | AU2392100A (de) |
| CA (1) | CA2354052A1 (de) |
| DE (1) | DE69911057D1 (de) |
| WO (1) | WO2000038785A2 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6953668B1 (en) | 1992-11-05 | 2005-10-11 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
| US7105159B1 (en) | 1992-11-05 | 2006-09-12 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
| US7070782B1 (en) | 1992-11-05 | 2006-07-04 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
| US6569432B1 (en) * | 1995-02-24 | 2003-05-27 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
| EP0812356B1 (de) | 1995-02-24 | 2006-02-08 | Sloan-Kettering Institute For Cancer Research | Prostataspezifisches membranes antigen und seine anwendungen |
| US20040253246A1 (en) * | 1996-02-23 | 2004-12-16 | Israeli Ron S. | Prostate-specific membrane antigen and uses thereof |
| US6444657B1 (en) * | 1998-12-31 | 2002-09-03 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
| JP3400798B2 (ja) * | 1999-09-14 | 2003-04-28 | 明治製菓株式会社 | カルボキシペプチダーゼｂ阻害活性を有するホスホン酸誘導体 |
| WO2001092273A2 (en) * | 2000-05-30 | 2001-12-06 | Guilford Pharmaceuticals Inc. | Benzenedicarboxylic acid derivatives |
| ATE337011T1 (de) * | 2001-02-07 | 2006-09-15 | Beth Israel Hospital | Modifizierte psma-liganden und deren verwendung |
| US7714020B2 (en) * | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
| AU2002303856A1 (en) | 2001-05-24 | 2002-12-03 | Neuronz Limited | Gpe analogs and peptidomimetics |
| US7605177B2 (en) * | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
| US20070004641A1 (en) * | 2001-05-24 | 2007-01-04 | Neuren Pharmaceuticals Limited | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate |
| US20050215472A1 (en) * | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| ES2559002T3 (es) * | 2001-10-23 | 2016-02-10 | Psma Development Company, L.L.C. | Anticuerpos contra PSMA |
| WO2003057670A2 (en) * | 2001-12-28 | 2003-07-17 | Guilford Pharmaceuticals Inc. | Indoles as naaladase inhibitors |
| DK1599461T3 (da) | 2003-03-03 | 2009-08-17 | Eisai Corp North America | Thiolactoner som NAALADase-inhibitorer |
| DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
| EP2672971A4 (de) * | 2011-02-11 | 2014-12-31 | Pharmalundensis Ab | Metabotrope glutamatrezeptor-gruppe-i-antagonisten zur behandlung abnormaler gewebeverbindungen |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5162512A (en) | 1982-03-09 | 1992-11-10 | Cytogen Corporation | Amine derivatives of anthracycline antibodies |
| US4950738A (en) | 1984-09-13 | 1990-08-21 | Cytogen Corporation | Amine derivatives of anthracycline antibiotics |
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US5140104A (en) | 1982-03-09 | 1992-08-18 | Cytogen Corporation | Amine derivatives of folic acid analogs |
| US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4857637A (en) | 1986-05-07 | 1989-08-15 | Genentech, Inc. | Methods and compositions for immunologically modulating growth hormone receptor activity |
| US4906779A (en) | 1986-07-10 | 1990-03-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
| US5093525A (en) | 1986-07-10 | 1992-03-03 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
| US5190976A (en) | 1986-07-10 | 1993-03-02 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And University Of Oregon | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
| CA1305177C (en) | 1987-06-30 | 1992-07-14 | Yasufumi Ohfune | Carboxycyclopropylglycine and process for producing the same |
| US4918064A (en) | 1987-10-21 | 1990-04-17 | G. D. Searle & Co. | Phenyl glycines for use in reducing neurotoxic injury |
| US5871472A (en) | 1987-11-17 | 1999-02-16 | Brown University Research Foundation | Planting devices for the focal release of neuroinhibitory compounds |
| US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
| EP0325224B1 (de) | 1988-01-22 | 1996-07-31 | ZymoGenetics, Inc. | Verfahren zur Herstellung von sekretierten Rezeptoranalogen |
| US4937183A (en) | 1988-02-03 | 1990-06-26 | Cytogen Corporation | Method for the preparation of antibody-fragment conjugates |
| US5047227A (en) | 1988-02-08 | 1991-09-10 | Cytogen Corporation | Novel and improved antibodies for site specific attachment of compounds |
| US5162504A (en) | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
| US4966999A (en) | 1988-06-07 | 1990-10-30 | Cytogen Corporation | Radiohalogenated compounds for site specific labeling |
| CA2002011A1 (en) | 1988-11-14 | 1990-05-14 | Anthony F. Purchio | Normal human growth regulatory receptor for tgf-beta |
| US4994446A (en) | 1989-01-03 | 1991-02-19 | Ramot - University Authority For Applied Research And Industrial Development Ltd. | Drug system |
| US5136080A (en) | 1989-12-04 | 1992-08-04 | Burroughs Wellcome Co. | Nitrile compounds |
| US5336689A (en) | 1990-03-02 | 1994-08-09 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists |
| US5262568A (en) | 1990-03-02 | 1993-11-16 | State Of Oregon | Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists |
| US5137877B1 (en) | 1990-05-14 | 1996-01-30 | Bristol Myers Squibb Co | Bifunctional linking compounds conjugates and methods for their production |
| GB9106678D0 (en) | 1991-03-28 | 1991-05-15 | Ferguson Mark W J | Wound healing |
| US5506107A (en) | 1991-05-10 | 1996-04-09 | Genentech, Inc. | Selecting ligand agonists and antagonists |
| JP2632754B2 (ja) | 1991-05-21 | 1997-07-23 | 塩野義製薬株式会社 | 脳内グルタミン酸遊離抑制剤 |
| US5229495A (en) | 1991-06-18 | 1993-07-20 | Ludwig Institute For Cancer Research | Substantially pure receptor like TGF-β 1 binding molecules and uses thereof |
| US5216126A (en) | 1991-06-19 | 1993-06-01 | Genentech, Inc. | Receptor polypeptides and their production and uses |
| US5543143A (en) | 1992-03-06 | 1996-08-06 | Corixa Corporation | Method for activating macrophages/monocytes |
| AU3920693A (en) | 1992-03-18 | 1993-10-21 | General Hospital Corporation, The | Four novel receptors of the TGF-beta receptor family |
| US5326856A (en) | 1992-04-09 | 1994-07-05 | Cytogen Corporation | Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding |
| US5668118A (en) * | 1992-07-24 | 1997-09-16 | Cavalier Pharmaceuticals | Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G |
| US5489525A (en) | 1992-10-08 | 1996-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Monoclonal antibodies to prostate cells |
| AU669256B2 (en) | 1992-10-29 | 1996-05-30 | Celtrix Pharmaceuticals, Inc. | Uses of TGF-beta receptor fragment as a therapeutic agent |
| JP4204642B2 (ja) | 1992-11-05 | 2009-01-07 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | 前立腺に特異的な膜抗原 |
| US5565439A (en) | 1992-11-24 | 1996-10-15 | The Procter & Gamble Company | Methods of using lysophosphatidic acid for treating hyperproliferative conditions |
| US5614502A (en) * | 1993-01-15 | 1997-03-25 | The General Hospital Corporation | High-pressure impulse transient drug delivery for the treatment of proliferative diseases |
| US5453492A (en) | 1993-07-28 | 1995-09-26 | La Jolla Cancer Research Foundation | 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β |
| US5449761A (en) | 1993-09-28 | 1995-09-12 | Cytogen Corporation | Metal-binding targeted polypeptide constructs |
| US5500420A (en) | 1993-12-20 | 1996-03-19 | Cornell Research Foundation, Inc. | Metabotropic glutamate receptor agonists in the treatment of cerebral ischemia |
| US5583153A (en) * | 1994-10-06 | 1996-12-10 | Regents Of The University Of California | Use of taxol in the treatment of rheumatoid arthritis |
| US6011021A (en) | 1996-06-17 | 2000-01-04 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
| US5698402A (en) | 1995-02-23 | 1997-12-16 | Dianon Systems, Inc. | Methods for diagnosing benign prostatic hyperplasia |
| EP0812356B1 (de) | 1995-02-24 | 2006-02-08 | Sloan-Kettering Institute For Cancer Research | Prostataspezifisches membranes antigen und seine anwendungen |
| US5616561A (en) | 1995-03-31 | 1997-04-01 | Regents Of The University Of California | TGF-β antagonists as mitigators of radiation-induced tissue damage |
| US5795877A (en) | 1996-12-31 | 1998-08-18 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
| US5804602A (en) | 1996-06-17 | 1998-09-08 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
| US6025345A (en) | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
| US5977090A (en) | 1996-09-27 | 1999-11-02 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors |
| US6017903A (en) | 1996-09-27 | 2000-01-25 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors |
| US6025344A (en) | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Certain dioic acid derivatives useful as NAALADase inhibitors |
| US5672592A (en) | 1996-06-17 | 1997-09-30 | Guilford Pharmaceuticals Inc. | Certain phosphonomethyl-pentanedioic acid derivatives thereof |
| US6046180A (en) | 1996-06-17 | 2000-04-04 | Guilford Pharmaceuticals Inc. | NAALADase inhibitors |
| US6054444A (en) | 1997-04-24 | 2000-04-25 | Guilford Pharmaceuticals Inc. | Phosphonic acid derivatives |
| US6384022B1 (en) | 1996-06-17 | 2002-05-07 | Guilford Pharmaceuticals Inc. | Prodrugs of NAALAdase inhibitors |
| US6071965A (en) | 1996-06-17 | 2000-06-06 | Guilford Pharmaceuticals Inc. | Phosphinic alkanoic acid derivatives |
| US5824662A (en) | 1996-09-27 | 1998-10-20 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using naaladase inhibitors |
| US5902817A (en) | 1997-04-09 | 1999-05-11 | Guilford Pharmaceuticals Inc. | Certain sulfoxide and sulfone derivatives |
| US5863536A (en) | 1996-12-31 | 1999-01-26 | Guilford Pharmaceuticals Inc. | Phosphoramidate derivatives |
| KR20000036227A (ko) * | 1996-09-27 | 2000-06-26 | 토마스 씨. 서 | 날라다아제조성물, 글루탐산염 이상 치료법 및 동물내의 뉴우런활성법 |
| US5962521A (en) | 1997-04-04 | 1999-10-05 | Guilford Pharmaceuticals Inc. | Hydroxamic acid derivatives |
| US5830210A (en) | 1996-10-21 | 1998-11-03 | Plc Medical Systems, Inc. | Catheter navigation apparatus |
| WO1998053812A1 (en) | 1997-05-27 | 1998-12-03 | Guilford Pharmaceuticals Inc. | Inhibitors of naaladase enzyme activity |
| CA2300135A1 (en) | 1997-08-14 | 1999-02-25 | Department Of The Army, U.S. Government | Treatment or prophylaxis of retinal pathology and spinal cord injury |
| US5981209A (en) | 1997-12-04 | 1999-11-09 | Guilford Pharmaceuticals Inc. | Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia |
| US6028216A (en) | 1997-12-31 | 2000-02-22 | Guilford Pharmaceuticals Inc. | Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives |
| US6121252A (en) | 1998-03-30 | 2000-09-19 | Guilford Pharmaceuticals Inc. | Phosphinic acid derivatives |
| CA2337797C (en) | 1998-07-06 | 2009-04-14 | Guilford Pharmaceuticals Inc. | Naaladase inhibitors useful as pharmaceutical compounds and compositions |
| US6265609B1 (en) * | 1998-07-06 | 2001-07-24 | Guilford Pharmaceuticals Inc. | Thio-substituted pentanedioic acid derivatives |
| US6395718B1 (en) * | 1998-07-06 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors |
| US6348329B1 (en) * | 1998-11-06 | 2002-02-19 | Fibrogen, Inc. | Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use |
| US6444657B1 (en) * | 1998-12-31 | 2002-09-03 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
| US6228888B1 (en) | 1999-07-01 | 2001-05-08 | Guilford Pharmaceuticals Inc. | Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors |
| US6313159B1 (en) | 1999-08-20 | 2001-11-06 | Guilford Pharmaceuticals Inc. | Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors |
-
1999
- 1999-10-22 US US09/425,197 patent/US6444657B1/en not_active Expired - Fee Related
- 1999-12-29 AU AU23921/00A patent/AU2392100A/en not_active Abandoned
- 1999-12-29 JP JP2000590733A patent/JP2002533421A/ja active Pending
- 1999-12-29 DE DE69911057T patent/DE69911057D1/de not_active Expired - Lifetime
- 1999-12-29 EP EP99967675A patent/EP1140048B1/de not_active Expired - Lifetime
- 1999-12-29 WO PCT/US1999/031039 patent/WO2000038785A2/en not_active Ceased
- 1999-12-29 CA CA002354052A patent/CA2354052A1/en not_active Abandoned
- 1999-12-29 AT AT99967675T patent/ATE248592T1/de not_active IP Right Cessation
- 1999-12-29 EP EP03019536A patent/EP1371367A1/de not_active Withdrawn
-
2002
- 2002-08-01 US US10/209,011 patent/US6806261B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1140048A2 (de) | 2001-10-10 |
| US6806261B2 (en) | 2004-10-19 |
| AU2392100A (en) | 2000-07-31 |
| US6444657B1 (en) | 2002-09-03 |
| WO2000038785A2 (en) | 2000-07-06 |
| US20030017965A1 (en) | 2003-01-23 |
| JP2002533421A (ja) | 2002-10-08 |
| EP1371367A1 (de) | 2003-12-17 |
| EP1140048B1 (de) | 2003-09-03 |
| WO2000038785A3 (en) | 2000-09-21 |
| DE69911057D1 (de) | 2003-10-09 |
| CA2354052A1 (en) | 2000-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE248592T1 (de) | Verwendung von naaladase hemmern zur herstellung eines medikaments zur behandlung von bestimmten krankheiten | |
| Yao et al. | Biocompatibility and biodegradation of a bone composite containing tricalcium phosphate and genipin crosslinked gelatin | |
| Hawkins et al. | The role of laser fluence in cell viability, proliferation, and membrane integrity of wounded human skin fibroblasts following helium‐neon laser irradiation | |
| Murray | Keloids and hypertrophic scars | |
| Chandra et al. | Peroxide‐based oxygen generating topical wound dressing for enhancing healing of dermal wounds | |
| Andreassi et al. | A new model of epidermal culture for the surgical treatment of vitiligo | |
| Heng | Wound healing in adult skin: aiming for perfect regeneration | |
| Carriel et al. | Combination of fibrin-agarose hydrogels and adipose-derived mesenchymal stem cells for peripheral nerve regeneration | |
| Leong et al. | Mesenchymal stem cells in tendon repair and regeneration: basic understanding and translational challenges | |
| Houreld et al. | In vitro exposure of wounded diabetic fibroblast cells to a helium-neon laser at 5 and 16 J/cm2 | |
| Abedin‐Do et al. | Electrical stimulation promotes the wound‐healing properties of diabetic human skin fibroblasts | |
| Swope et al. | Regulation of cutaneous pigmentation by titration of human melanocytes in cultured skin substitutes grafted to athymic mice | |
| DE69525151D1 (de) | Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat | |
| ATE125158T1 (de) | Biologisch abbaubare und biologisch absorbierbare führungskanäle zur verwendung in der behandlung und regenerierung von nerven. | |
| DE69533223D1 (de) | Zusammensetzungen und verfahren zur stimulierung der proliferation und der differenzierung von menschlichen fetalen und erwachsenen pankreatischen zellen ex vivo | |
| Liu et al. | Autologous cultured keratinocytes on porcine gelatin microbeads effectively heal chronic venous leg ulcers | |
| Chiu et al. | Tissue engineering-based strategies for diabetic foot ulcer management | |
| Elliott et al. | Initial experience with cultured epithelial autografts in massively burnt patients | |
| DE50014532D1 (de) | Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz | |
| Lv et al. | An experimental novel study: hyperbaric oxygen treatment on reduction of epidural fibrosis via down-regulation of collagen deposition, IL-6, and TGF-β1 | |
| ATE352306T1 (de) | Ein präkursor der harnsäure und ein antioxidationsmittel enthaltende zusammensetzung und deren verwendung zur behandlung von neurodegenerativen erkrankungen | |
| WO2004011631A3 (en) | Methods and compositions for treating tissue defects using pulsed electromagnetic field stimulus | |
| Fimiani et al. | Other uses of homologous skin grafts and skin bank bioproducts | |
| Wu et al. | Melatonin-loaded hydrogel modulates circadian rhythms and alleviates oxidative stress and inflammation to promote wound healing | |
| Morimoto et al. | An evaluation of the engraftment and the blood flow of porcine skin autografts inactivated by high hydrostatic pressure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |